DRAD Digirad Corporation

Digirad Corporation (NASDAQ:DRAD), a leading provider of cardiovascular imaging services and solid-state nuclear medicine imaging products to physician offices, hospitals and imaging centers, announced today the release of the new Cardius(R) 3 XPO triple-head cardiac gamma camera at the Society of Nuclear Medicine meeting in San Diego, California. The Cardius 3 XPO imaging system introduces new Solidium(R) high-definition solid-state (HDSD) digital detector technology, a new design that allows imaging of patients weighing up to 500 pounds and offers up to 38% faster image acquisition times than conventional dual head systems. The Cardius 3 XPO is all about delivering more patient comfort, enhanced clarity of diagnostic results, achieving greater imaging speed and producing images of superb quality. "We believe that the new Cardius 3 XPO system represents yet another major leap forward in Digirad's solid-state technology by enhancing patient comfort, image quality and speed in nuclear cardiac SPECT examinations," reported Randy Weatherhead, Senior Vice President of Marketing and Sales. He further commented, "The new high-definition solid-state detectors represent a major advancement over traditional anger detectors in performance and serviceability. Truly the time has come for nuclear medicine facilities to take a serious look at the benefits of Digirad's solid-state technology." About Digirad Digirad Corporation develops, manufactures and markets solid-state, digital gamma cameras to hospitals, imaging centers and physician offices. Digirad offers a comprehensive line of solid-state nuclear gamma cameras that produce high-quality images for use in the detection of many medical conditions, including cardiovascular disease. Digirad's cameras are unique as their lightweight and compact design allows them to fit easily into small office spaces. Digirad's wholly owned subsidiaries, Digirad Imaging Solutions and Digirad Imaging Systems, offer a comprehensive, mobile imaging leasing and services program for physicians who wish to perform in-office nuclear cardiology procedures but do not have the patient volume, capital or resources to justify purchasing a gamma camera. For more information, please visit www.digirad.com. Digirad(R), Cardius(R) and Solidium(R) are registered trademarks of Digirad Corporation. Forward-Looking Statements Digirad cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning in connection with a discussion of future operating or financial performance or events. Examples of such statements include the statements regarding the Cardius(R) 3 XPO's advancements in patient comfort, imaging speed and image quality, Digirad's ability to meet customer expectations and regulatory requirements, and Digirad's ability to design, develop, produce, install and service medical devices and related services. The inclusion of these and other forward-looking statements should not be regarded as a representation by Digirad that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Digirad's business including, without limitation: the degree to which personnel changes and related disruptions in our business activities may affect Digirad's products, customers, work force, suppliers, and our overall business prospects and operations; the degree to which Digirad's camera systems and related services will be accepted by physicians and hospitals some of whom may experience reliability issues or technical problems; the ability of Digirad to effectively market, sell and distribute its medical devices, and related services given its limited capabilities in these areas; Digirad's ability to manage risks relating to product liability, warranty claims, recalls, property damage and personal injury with respect to its imaging systems; and other risks detailed in Digirad's Securities and Exchange Commission filings, including its Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Digirad undertakes no obligation to revise or update this press release including the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.